Retinal Function in Parkinson's Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by Edward Hines Jr. VA Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Edward Hines Jr. VA Hospital
ClinicalTrials.gov Identifier:
NCT01010074
First received: November 6, 2009
Last updated: NA
Last verified: November 2009
History: No changes posted
  Purpose

Parkinson's disease (PD) is a neurodegenerative disorder characterized by muscle rigidity, tremor, a slowing of physical movement (bradykinesia) and, in extreme cases, a loss of physical movement. The primary symptoms are the results of decreased stimulation of the motor cortex arising from the basal ganglia normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Secondary symptoms may include high level cognitive dysfunction and subtle language problems. Included in the symptomatology experienced by patients with PD, visual abnormalities are not uncommon. Visual changes among patients with PD appear not only dynamic in nature, but differentially affected based on the course of the disease and, perhaps more importantly, its treatment. Parkinson's disease has significant ramifications not only in observation of irregularities in vision, but how vision interacts with entrainment of the circadian clock. The purpose of this study is to examine the relationship between PD and operation of a unique set of retinal cells known to regulate the circadian clock and sleep-wake cycles in human subjects.


Condition
Parkinson's Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Intrinsically Photosensitive Retinal Ganglion Cells in Parkinson's Disease

Resource links provided by NLM:


Further study details as provided by Edward Hines Jr. VA Hospital:

Primary Outcome Measures:
  • pupillary threshold [ Time Frame: one ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: October 2009
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

movement disorders/neurology clinic

Criteria

Inclusion Criteria: age 18-64 best corrected visual acuity of 20/25 or better in each eye -

Exclusion Criteria: evidence of any form of eye disease, inability to understand and sign informed consent.

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01010074

Contacts
Contact: Bruce Ira Gaynes, OD, PharmD 708-216-6262 Bruce.Gaynes@va.gov
Contact: Jasvinder Chawla, MD 708-202-3800 Jasvinder.Chawla@va.gov

Locations
United States, Illinois
Hines VA Medical Center Recruiting
Hines, Illinois, United States, 60141
Contact: Bruce Ira Gaynes, OD, PharmD    708-216-6262    Bruce.Gaynes@va.gov   
Sponsors and Collaborators
  More Information

No publications provided

Responsible Party: Bruce I. Gaynes, OD, PharmD, Hines VA Medical Center
ClinicalTrials.gov Identifier: NCT01010074     History of Changes
Other Study ID Numbers: PD001
Study First Received: November 6, 2009
Last Updated: November 6, 2009
Health Authority: United States: Federal Government

Keywords provided by Edward Hines Jr. VA Hospital:
retina, Parkinson's disease, ganglion cell, pupillary

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on July 26, 2014